Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients With Cardiovascular History Trial
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background— Rosiglitazone has several properties that may affect progression of atherosclerosis. The Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients With Cardiovascular History (APPROACH) study was undertaken to determine the effect of the thiazolidinedione rosiglitazone on coronary atherosclerosis as assessed by intravascular ultrasound compared with the sulfonylurea glipizide. Methods and Results— This was a randomized, double-blind, controlled 18-month study in 672 patients aged 30 to 80 years with established type 2 diabetes mellitus treated by lifestyle, 1 oral agent, or submaximal doses of 2 oral agents who had at least 1 atherosclerotic plaque with 10% to 50% luminal narrowing in a coronary artery that had not undergone intervention during a clinically indicated coronary angiography or percutaneous coronary intervention. The primary outcome was change in percent atheroma volume in the longest and least angulated epicardial coronary artery that had not undergone intervention. Secondary outcomes included change in normalized total atheroma volume and change in total atheroma volume in the most diseased baseline 10-mm segment. Rosiglitazone did not significantly reduce the primary outcome of percent atheroma volume compared with glipizide (−0.64%; 95% confidence interval, −1.46 to 0.17; P =0.12). The secondary outcome of normalized total atheroma volume was significantly reduced by rosiglitazone compared with glipizide (−5.1 mm 3 ; 95% confidence interval, −10.0 to −0.3; P =0.04); however, no significant difference between groups was observed for the change in total atheroma volume within the most diseased baseline 10-mm segment (−1.7 mm 3 ; 95% confidence interval, −3.9 to 0.5; P =0.13). Conclusions— Rosiglitazone did not significantly decrease the primary end point of progression of coronary atherosclerosis more than glipizide in patients with type 2 diabetes mellitus and coronary atherosclerosis. Clinical Trial Registration— http://www.clinicaltrials.gov. Unique Identifier: NCT00116831.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“9) and a mean (SD) of 16 (6) months; patients allocated to glipizide were adherent (took 80% and 120% of their study medications) at 90.”
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Self-citationEffect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Self-citationNissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F. L., Powe, N. R., & Golden, S. H. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00007 · Cited by 1,657
Tiikkainen, M., Häkkinen, A.-M., Korsheninnikova, E., Nyman, T., Mäkimattila, S., & Yki-Järvinen, H. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2169 · Cited by 524
Shuster, J. J., Jones, L. S., & Salmon, D. A. (2007) · Statistics in Medicine · doi:10.1002/sim.3060 · Cited by 105
Research works printed but not linked: 27
- 10.1136/bmj.38678.389583.7C · DOI · Paper page
- 10.1016/S0140-6736(98)07037-8 · DOI · Paper page
- 10.1016/S0002-8703(03)00239-4 · doi:10.1016/s0002-8703(03)00239-4
- 10.1161/01.cir.0000142048.94084.ca · DOI
- 10.1001/jama.292.18.2217 · DOI · Paper page
- 10.1001/jama.291.9.1071 · DOI · Paper page
- 10.1161/01.cir.0000140261.58966.a4 · DOI · Paper page
- 10.1161/circ.104.4.387 · doi:10.1161/circ.104.4.387
- 10.1016/S0002-9149(97)00221-X · DOI
- 10.1161/01.cir.0000025403.20953.23 · DOI · Paper page
- 10.2337/diacare.27.6.1349 · DOI · Paper page
- 10.1592/phco.25.5.637.63587 · DOI
- 10.1177/1358863X07084200 · DOI
- 10.1111/j.1524-6175.2005.04784.x · DOI · Paper page
- 10.1001/jama.296.21.joc60158 · DOI · Paper page
- 10.1016/j.ahj.2007.04.005 · DOI
- 10.1001/jama.299.13.1561 · DOI · Paper page
- 10.1016/j.ahj.2008.07.025 · DOI
- 10.1002/ccd.10693 · DOI
- 10.1016/j.amjcard.2007.02.073 · DOI
- 10.1016/S0197-2456(99)00022-7 · DOI · Paper page
- Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J. 2007; 153: 445–446.
- 10.2337/dc06-1854 · DOI · Paper page
- 10.1001/jama.298.10.1189 · DOI · Paper page
- 10.1016/S0140-6736(07)61514-1 · DOI · Paper page
- 10.1186/1756-0500-2-5 · DOI
- Mannucci E Monami M Di Bari M Lamanna C Gori F Gensini GF Marchionni N. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. Int J Cardiol. Mar 26 2009. DOI: 10.1016/j.ijcard.2009.01.064. Available at: http://www.internationaljournalofcardiology.com/article/S0167-5273%2809%2900133-8/fulltext/. Accessed September 12 2009. · DOI
Cited by
Palmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Nissen, S. E., & Wolski, K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.207 · Cited by 594
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Handelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513
Metadata
- Authors
- Gerstein, H. C., Ratner, R. E., Cannon, C. P., Serruys, P. W., García-García, H. M., van Es, G.-A., Kolatkar, N. S., Kravitz, B. G., Miller, D. M., Huang, C., Fitzgerald, P. J., Nesto, R. W., & the APPROACH Study Group
- Venue
- Circulation
- Published
- 2010-03-16
- Volume
- 121
- Issue
- 10
- Pages
- 1176-1187
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2135683342
- Cited by
- 103
- References
- 9
- FWCI
- 13.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients With Cardiovascular History Trial. https://app.cochat.ai/papers/10.1161/circulationaha.109.881003
- The paper
- Gerstein, H. C., Ratner, R. E., Cannon, C. P., Serruys, P. W., García-García, H. M., van Es, G.-A., Kolatkar, N. S., Kravitz, B. G., Miller, D. M., Huang, C., Fitzgerald, P. J., Nesto, R. W., & the APPROACH Study Group. (2010). Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients With Cardiovascular History Trial. Circulation. https://doi.org/10.1161/circulationaha.109.881003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.